A pharmaceutical composition in a solid oral dosage form comprising: a. a core containing i. a therapeutically effective amount of at least one conjugated estrogen selected from the group consisting of 17-alpha-dihydroequilin, 17-beta-dihydroequilin, equilenin, 17-alpha-dihydroequilenin, 17-betadihydroequilenin, estrone, 17-beta-estradiol, estropipate, ethinyl estradiol, and esters thereof, or a component thereof, optionally wherein the conjugated estrogen is a mixture of estrogenic components, and optionally, other hormones; ii. at least one organic excipient, wherein the at least one organic excipient comprises 25% w/w or less of a cellulose ingredient based on the weight of the pharmaceutical composition, iii. less than 50% w/w of a sugar ingredient based on the weight of the pharmaceutical composition, iv. at least one inorganic excipient, wherein the at least one inorganic excipient includes a calcium phosphate tribasic in an amount of from 0.5% w/w to 20% w/w; and b. a pharmaceutically acceptable coating that is free of hormones and microcrystalline cellulose; wherein there is an absence of a substantial amount of a moisture barrier imparting polymer as an outer coat; and wherein the composition does not crack when stored at 40°C and 75% relative humidity for two months. a. a core containing i. a therapeutically effective amount of at least one conjugated estrogen selected from the group consisting of 17-alpha-dihydroequilin, 17-beta-dihydroequilin, equilenin, 17-alpha-dihydroequilenin, 17-betadihydroequilenin, estrone, 17-beta-estradiol, estropipate, ethinyl estradiol, and esters thereof, or a component thereof, optionally wherein the conjugated estrogen is a mixture of estrogenic components, and optionally, other hormones; ii. at least one organic excipient, wherein the at least one organic excipient comprises 25% w/w or less of a cellulose ingredient based on the weight of the pharmaceutical composition, iii. less than 50% w/w of a sugar ingredient based on the weight of the pharmaceutical composition, iv. at least one inorganic excipient, wherein the at least one inorganic excipient includes a calcium phosphate tribasic in an amount of from 0.5% w/w to 20% w/w; and i. a therapeutically effective amount of at least one conjugated estrogen selected from the group consisting of 17-alpha-dihydroequilin, 17-beta-dihydroequilin, equilenin, 17-alpha-dihydroequilenin, 17-betadihydroequilenin, estrone, 17-beta-estradiol, estropipate, ethinyl estradiol, and esters thereof, or a component thereof, optionally wherein the conjugated estrogen is a mixture of estrogenic components, and optionally, other hormones; ii. at least one organic excipient, wherein the at least one organic excipient comprises 25% w/w or less of a cellulose ingredient based on the weight of the pharmaceutical composition, iii. less than 50% w/w of a sugar ingredient based on the weight of the pharmaceutical composition, iv. at least one inorganic excipient, wherein the at least one inorganic excipient includes a calcium phosphate tribasic in an amount of from 0.5% w/w to 20% w/w; and b. a pharmaceutically acceptable coating that is free of hormones and microcrystalline cellulose;